LIMS product deployed by top-five pharma company

Sapio Sciences has licensed its Exemplar LIMS product to one of the top five pharmaceutical companies in the world, to help organise its genetics research.

The pharma company currently produces thousands of samples, which could soon grow into millions in the near future. The software provides straightforward wizards to handle the samples automatically, which may then be tracked using 1D and 2D barcodes. The built in reagent protocols for Illumina and Affymetrix platforms eliminate the need for paper tracking of lab procedures.

If this approach seems to be verging on the ELN market, it was wholly deliberate, according to Kevin Cramer, CEO at Sapio, who says the product also integrates bioinformatics systems. ‘We felt from the beginning that intuitively all these product categories should really be one product. In fact, we are going to extend that definition even further to say that certain analytics results and even clinical trial management should be part of a complete LIMS solution.’

The Exemplar LIMS BioBanking module helps the laboratories of the company, whose name has not been disclosed, to adhere to Good Laboratory Practices regulations and FDA CFP 11 Part 21 patent regulations.

Twitter icon
Google icon icon
Digg icon
LinkedIn icon
Reddit icon
e-mail icon

Gemma Church finds out how astronomers are using simulations to investigate the extremities of our universe


Turning data into scientific insight is not a straightforward matter, writes Sophia Ktori


The Leibniz Supercomputing Centre (LRZ) is driving the development of new energy-efficient practices for HPC, as Robert Roe discovers


William Payne investigates the growing trend of using modular HPC, built on industry standard hardware and software, to support users across a range of both existing and emerging application areas


Robert Roe looks at developments in crash testing simulation – including larger, more intricate simulations, the use of optimisation software, and the development of new methodologies through collaboration between ISVs, commercial companies, and research organisations